Methylprednisolone

證據等級: L5

預測適應症: 10 個

Methylprednisolone: From Corticosteroid-Responsive Inflammatory Conditions to Alopecia Areata

One-Sentence Summary

Methylprednisolone is a systemic glucocorticoid broadly used across corticosteroid-responsive inflammatory, allergic, and autoimmune conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 18 clinical trials and 20 publications currently retrieved in relation to this direction — though only a subset directly studies methylprednisolone itself in alopecia areata, most others being reference trials in related autoimmune disease (SLE) with different drugs.

Quick Overview

Item	Content
Original Indication	Not specified in this evidence pack (no SAHPRA license/indication text available). Methylprednisolone is a broad-spectrum systemic corticosteroid generally used for inflammatory, allergic, and autoimmune conditions.
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L3
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (Data Gap DG002). Based on known pharmacology, methylprednisolone is a synthetic glucocorticoid; its anti-inflammatory and immunosuppressive efficacy across corticosteroid-responsive conditions has been well established, and mechanistically this activity may extend to alopecia areata.

Alopecia areata is a T-cell mediated autoimmune attack on the hair follicle. Methylprednisolone, as a broad-spectrum glucocorticoid, suppresses T-cell activation and local inflammatory cytokines (e.g. IFN-γ, IL-15) that drive collapse of the hair follicle’s immune-privileged status. This mechanistic link is well supported — oral and intravenous “pulse” methylprednisolone regimens are already established, commonly used dermatology practice for severe/extensive alopecia areata, which is consistent with the TxGNN model’s high prediction score.

Several retrieved trials are not directly about methylprednisolone in alopecia areata but instead concern other drugs (e.g. baricitinib, VIB7734) in systemic lupus erythematosus, a related autoimmune disease. These are included in the evidence pack as population/endpoint reference only and should not be read as direct efficacy evidence for this specific drug-indication pair.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Oral mega-pulse methylprednisolone in severe therapy-resistant alopecia areata (totalis/universalis/ophiasic); directly tests the drug-indication pair.
NCT01017510	N/A	Unknown	20	Compared DERMOJET vs. conventional syringe for intralesional corticosteroid injection in alopecia areata; small study, drug class relevant but not methylprednisolone-specific comparator trial.
NCT07101471	N/A (Observational)	Completed	296	Safety/effectiveness of tofacitinib in alopecia, with some participants on adjuvant prednisolone; indirect reference.
NCT03616964	Phase 3	Completed	778	Baricitinib (JAK inhibitor) in systemic lupus erythematosus — same broader autoimmune disease area, different drug/mechanism; reference only, not alopecia-specific.
NCT04925934	Phase 2	Completed	214	VIB7734 (anti-ILT7 mAb) in systemic lupus erythematosus — different drug/mechanism; reference only.

Note: The evidence pack also retrieved additional trials (e.g. in SLE, prostate cancer, headache, nephrotic syndrome) under this drug-disease query; these were excluded above as low direct relevance to alopecia areata and are not shown.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30745958	2019	RCT (combination therapy)	Open Access Maced J Med Sci	Methotrexate + mini-pulse methylprednisolone in severe alopecia areata (Vietnamese cohort).
32270396	2020	Systematic Review	Dermatology and Therapy	Cyclosporine with and without systemic corticosteroids in alopecia areata treatment.
37992355	2023	Review	Dermatol Pract Concept	Efficacy and adverse effects of corticosteroid pulse therapy in alopecia areata.
28378336	2017	Review	Int J Dermatol	Review of treatment options for alopecia totalis and alopecia universalis.
36461625	2023	Review (pediatric dosing)	Pediatric Dermatology	Pulse-dose corticosteroid therapy dosing/administration in pediatric alopecia areata.
35986630	2022	Cohort (retrospective)	Dermatologic Therapy	Methylprednisolone alone vs. combined with methotrexate in extensive alopecia areata.
25566921	2015	Cohort (case series)	Indian J Dermatol Venereol Leprol	IV methylprednisolone pulse therapy in severe alopecia areata.
36865845	2022	Cohort (retrospective)	Indian J Dermatol	Sex differences in alopecia areata treated with steroid pulse therapy.
22426909	2012	Cohort (case series)	Saudi Med J	Efficacy and safety of oral mega-pulse methylprednisolone for severe therapy-resistant alopecia areata.
18608727	2008	Case series	J Dermatol Treat	Combination therapy of cyclosporine and methylprednisolone in severe alopecia areata.

South Africa Market Information

Methylprednisolone currently has 0 SAHPRA registrations on record in this evidence pack, and market status is listed as Not Marketed. No product registration details are available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: this evidence pack flags a Blocking data gap — DG001, TFDA/label warnings and contraindications not yet retrieved — which prevents a full S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple retrospective cohorts, case series, and reviews — plus one directly on-target Phase 4 study (NCT01167946) — support methylprednisolone pulse therapy in severe/extensive alopecia areata, consistent with existing dermatology clinical practice. However, no large Phase 3 RCT specifically evaluates methylprednisolone (as opposed to other drugs) in this indication, and several retrieved trials are only indirectly relevant (different drug, related disease), so evidence remains at L3.

To proceed, the following is needed:

TFDA/SAHPRA-approved Professional Information (PI) — warnings, contraindications (Blocking gap DG001)
Mechanism of action (MOA) data from DrugBank (High-priority gap DG002)
Confirmation of South Africa market/registration status, since currently listed as not marketed
A dedicated safety monitoring plan for pulse-dose corticosteroid use in alopecia areata patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.